Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
1(13%)
Results Posted
67%(2 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
1
13%
Ph phase_3
1
13%
Ph phase_4
1
13%
Ph not_applicable
3
38%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
3(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)
N/A3 (50.0%)

Trials by Status

active_not_recruiting113%
completed338%
terminated338%
withdrawn113%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
PROCEDURE
Total Trials
8